Systemic Inflammation Exacerbates Stroke in Patients with Left Ventricular Assist Device (P4.235)

CONCLUSIONS:In LVAD patients, total prevention of cerebrovascular complications cannot be accomplished only by adjusting warfarin dosage to meet the therapeutic range. However, recognition of increased CRP and appropriate management of inflammation prior to the stroke onset may enable us to avoid its aggravation and secure patient’s opportunity for heart transplantation.Disclosure: Dr. Ohtomo has nothing to disclose. Dr. Iwata has received personal compensation for activities with Janssen Pharmaceuticals, Eisai Inc., Daiichi Pharmaceutical Corp., Ono Pharmaceutical, and Takeda Pharmaceutical Co. Ltd. Dr. Iwata has received research support from Janssen Pharmaceuticals, Eisai Inc., and Daiichi Pharmaceutical Corporation. Dr. Kinoshita has nothing to disclose. Dr. Shimizu has nothing to disclose. Dr. Ono has nothing to disclose. Dr. Tsuji has nothing to disclose.

Source: Neurology - April 9, 2014 Category: Neurology Authors: Ohtomo, R., Iwata, A., Kinoshita, O., Shimizu, J., Ono, M., Tsuji, S. Tags: Cerebrovascular Disease and Interventional Neurology: Cardiac Source Type: research